Event-Driven Stocks

Cyclerion Therapeutics, Inc.

CYCNNasdaq

Healthcare · Pharmaceutical Preparations · MA · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$2.1M$2.0M$0$297,000$3.9M$2.3M
Operating income−$5.0M−$3.6M−$13.0M−$18.5M−$55.2M−$81.3M
Net income−$3.5M−$3.1M−$5.3M−$44.1M−$51.6M−$77.8M
Total assets$10.0M$9.6M$13.4M$18.1M$59.3M$115.4M
Total liabilities——————
Equity$9.1M$8.8M$11.3M$10.5M$48.2M$59.5M
EPS (diluted)$-1.11$-1.21$-2.25$-20.28$-1.32—
Shares out.2.7M2.7M43.5M43.4M34.1M27.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−239.8%
Net margin
−170.1%
Return on equity
−38.8%
Return on assets
−35.3%
Return on capital (ROCE)
−54.7%
Liabilities / assets
—
Debt / equity
—
Book value / share
$3.35
Revenue growth (YoY)
3.7%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−2.1%clean
Piotroski F-Score
2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
67
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 warning● 2 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202626,6631.0-52.9%
Apr 30, 202656,6181.0-78.8%
Apr 15, 2026267,3521.0+135.7%
Mar 31, 2026113,4483.4+34.2%
Mar 13, 202684,5481.9-10.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)